| Recommended (dose range) . | Not recommended . |
|---|---|
| Sulfonylureas | Sulfonylureas |
| Glipizide IR or Glipizide XR (5–10 mg/d) | Glyburide Gliclizide |
| Glimepiride (1–4 mg/d) | |
| Meglitinides | Biguinides |
| Nateglinide (60–120 mg with meals) | Metformin |
| Repaglinide (0.5–1 mg with meals) | |
| Thiazolidinediones | α-Glucosidase inhibitors |
| Pioglitazone (15–30 mg/d) | Acarbose |
| Miglitol | |
| Voglibose | |
| DPP-4 inhibitors | GLP-1 agonists |
| Alogliptin (6.25 mg/d) | Exenatide |
| Linagliptin (5 mg/d) | Exenatide XR |
| Saxagliptin (2.5 mg/d) | Liraglutide |
| Sitagliptin (25 mg/d) | Albiglutide |
| Vildagliptin (50 mg/d) | Dilaglutide |
| Insulin | SGLT-2 inhibitors |
| Short acting (Human regular) | Canagliflozin |
| Rapid-acting analogs (Aspart, Glulisine, Lispro) | Dapagliflozin Empagliflozin |
| Intermediate- and long-acting (NPH, Glargine, Detemir) | |
| Premixed | |
| Other hypoglycemic agents | |
| Bile acid resin (Colesevalam) | |
| Amylin analog (Pramlitinide) | |
| Dopamine agonist (Bromociptine) (quick release) |
| Recommended (dose range) . | Not recommended . |
|---|---|
| Sulfonylureas | Sulfonylureas |
| Glipizide IR or Glipizide XR (5–10 mg/d) | Glyburide Gliclizide |
| Glimepiride (1–4 mg/d) | |
| Meglitinides | Biguinides |
| Nateglinide (60–120 mg with meals) | Metformin |
| Repaglinide (0.5–1 mg with meals) | |
| Thiazolidinediones | α-Glucosidase inhibitors |
| Pioglitazone (15–30 mg/d) | Acarbose |
| Miglitol | |
| Voglibose | |
| DPP-4 inhibitors | GLP-1 agonists |
| Alogliptin (6.25 mg/d) | Exenatide |
| Linagliptin (5 mg/d) | Exenatide XR |
| Saxagliptin (2.5 mg/d) | Liraglutide |
| Sitagliptin (25 mg/d) | Albiglutide |
| Vildagliptin (50 mg/d) | Dilaglutide |
| Insulin | SGLT-2 inhibitors |
| Short acting (Human regular) | Canagliflozin |
| Rapid-acting analogs (Aspart, Glulisine, Lispro) | Dapagliflozin Empagliflozin |
| Intermediate- and long-acting (NPH, Glargine, Detemir) | |
| Premixed | |
| Other hypoglycemic agents | |
| Bile acid resin (Colesevalam) | |
| Amylin analog (Pramlitinide) | |
| Dopamine agonist (Bromociptine) (quick release) |
DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose cotransporter 2.
| Recommended (dose range) . | Not recommended . |
|---|---|
| Sulfonylureas | Sulfonylureas |
| Glipizide IR or Glipizide XR (5–10 mg/d) | Glyburide Gliclizide |
| Glimepiride (1–4 mg/d) | |
| Meglitinides | Biguinides |
| Nateglinide (60–120 mg with meals) | Metformin |
| Repaglinide (0.5–1 mg with meals) | |
| Thiazolidinediones | α-Glucosidase inhibitors |
| Pioglitazone (15–30 mg/d) | Acarbose |
| Miglitol | |
| Voglibose | |
| DPP-4 inhibitors | GLP-1 agonists |
| Alogliptin (6.25 mg/d) | Exenatide |
| Linagliptin (5 mg/d) | Exenatide XR |
| Saxagliptin (2.5 mg/d) | Liraglutide |
| Sitagliptin (25 mg/d) | Albiglutide |
| Vildagliptin (50 mg/d) | Dilaglutide |
| Insulin | SGLT-2 inhibitors |
| Short acting (Human regular) | Canagliflozin |
| Rapid-acting analogs (Aspart, Glulisine, Lispro) | Dapagliflozin Empagliflozin |
| Intermediate- and long-acting (NPH, Glargine, Detemir) | |
| Premixed | |
| Other hypoglycemic agents | |
| Bile acid resin (Colesevalam) | |
| Amylin analog (Pramlitinide) | |
| Dopamine agonist (Bromociptine) (quick release) |
| Recommended (dose range) . | Not recommended . |
|---|---|
| Sulfonylureas | Sulfonylureas |
| Glipizide IR or Glipizide XR (5–10 mg/d) | Glyburide Gliclizide |
| Glimepiride (1–4 mg/d) | |
| Meglitinides | Biguinides |
| Nateglinide (60–120 mg with meals) | Metformin |
| Repaglinide (0.5–1 mg with meals) | |
| Thiazolidinediones | α-Glucosidase inhibitors |
| Pioglitazone (15–30 mg/d) | Acarbose |
| Miglitol | |
| Voglibose | |
| DPP-4 inhibitors | GLP-1 agonists |
| Alogliptin (6.25 mg/d) | Exenatide |
| Linagliptin (5 mg/d) | Exenatide XR |
| Saxagliptin (2.5 mg/d) | Liraglutide |
| Sitagliptin (25 mg/d) | Albiglutide |
| Vildagliptin (50 mg/d) | Dilaglutide |
| Insulin | SGLT-2 inhibitors |
| Short acting (Human regular) | Canagliflozin |
| Rapid-acting analogs (Aspart, Glulisine, Lispro) | Dapagliflozin Empagliflozin |
| Intermediate- and long-acting (NPH, Glargine, Detemir) | |
| Premixed | |
| Other hypoglycemic agents | |
| Bile acid resin (Colesevalam) | |
| Amylin analog (Pramlitinide) | |
| Dopamine agonist (Bromociptine) (quick release) |
DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose cotransporter 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
